FDA Brief

Warning letters Drugs

FDA warning letter to

Custom Research Labs Inc.

High riskIssued Jul 8, 2022Posted Jul 26, 2022Division of Pharmaceutical Quality Operations IV

FDA warned Custom Research Labs Inc. about manufacturing-practice violations and unapproved, misbranded OTC drugs, including hand sanitizers and topical analgesics.

What happened

FDA inspected Custom Research Labs Inc.’s Gardena, CA drug manufacturing facility from June 1 to June 4, 2021, and reviewed the company’s June 10, 2021 response to a Form FDA 483 (inspection observations). FDA found significant current good manufacturing practice (CGMP) violations, including failure to test incoming components, inadequate water-system monitoring, lack of process validation, inadequate stability data, and quality-unit release of batches before batch-record review. FDA also reviewed product labeling and websites and found hand sanitizers and topical external analgesics marketed as unapproved new drugs and misbranded.

What FDA found

  1. FDA cited failure to test each incoming component lot for identity and other quality attributes and to qualify suppliers; the deionized water system also lacked total organic carbon and conductivity controls and had high microbial counts and out-of-specification pH.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The company made multiple batches of a drug product with an unvalidated manufacturing process and had them in distribution.

    21 CFR 211.100(a)
  3. The company lacked stability data to support the two-year expiration date for a drug product in distribution and relied on data from a different formulation that failed long-term stability testing.

    21 CFR 211.166(a)
  4. The quality unit released drug product batches before batch records were reviewed or completed.

    21 CFR 211.22
  5. The hand sanitizers and topical external analgesic products were unapproved new drugs because they lacked FDA approval and did not meet the applicable OTC monograph conditions.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  6. The products were misbranded (labeling violations) because of labeling and website claims.

    FD&C Act sections 502(c) and (ee), 21 U.S.C. 352(c) and (ee)

What FDA wants

FDA asks the company to correct the violations and provide comprehensive remediation plans and procedures for component testing and supplier qualification, water-system monitoring and design, process validation, stability testing, and quality-unit oversight. The provided text does not state a response deadline.

Who should pay attention

  • brands that buy OTC drugs from contract manufacturers
  • companies selling hand sanitizers or topical analgesics
  • quality teams managing supplier qualification and water systems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk